A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients. It demonstrated a weight gain in patients who took the drug versus a ...

Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (ARTL) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to ...

Artelo Biosciences, Inc. (NASDAQ:ARTL) on Wednesday released interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial with ART27.13, the company’s peripherally acting cannabinoid ...

University of Oklahoma researcher Min Li, Ph.D., is the lead author of a new publication in Cancer Cell about cancer cachexia. Cachexia is a muscle-wasting and fat-loss condition that most often ...

New research from the University of Oklahoma, published today in Cancer Cell, describes for the first time a "triangle regulation theory" of cancer-induced cachexia and anorexia. Cachexia is a ...

A majority of people with advanced cancers endure cachexia, a muscle-, fat-, and organ-wasting condition that is currently incurable and can be life-threatening. Detecting and intervening early can ...

Dietary Fat and Carbohydrates Are Independently Associated With Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor–Binding Protein 3 Concentrations in Healthy Adults PURPOSE: ...

For patients with advanced non-small cell lung cancer and anorexia, the use of the antidepressant Remeron has been shown to increase energy consumption, as researchers look for therapies to answer an ...

The optimal therapy for anorexia and cachexia is curing the underlying cancer. [23] Unfortunately, this goal is often not attainable with currently available treatments. Thus, an integrated ...

Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo The Phase 2 ...